In humans, the chicken ovalbumin upstream promoter transcription factor (COUP-TF) family, a subfamily of the nuclear receptor superfamily (27, 39, 54, 60, 61) , comprises at least three proteins, namely, COUP-TFI (also designated ErbArelated protein-3 [EAR3]) (42, 61) , COUP-TFII (also termed apolipoprotein-AI [apo-AI] regulatory protein-1 [ARP-1]) (26) , and EAR2 (42) . As no specific ligand for these proteins has been identified so far, they are classified as orphan receptors. Members of the COUP-TF family are potent repressors of the transcriptional activities of multiple genes, including several apolipoprotein-encoding genes (25, 47-50, 55, 64, 65) , the ␣-fetoprotein gene (32) , the erythropoietin gene (17) , the oxytocin gene (35, 62) , and numerous others (1, 6, 33, 34) . A considerable number of genes, such as the arrestin gene (36) , the vHNF-1 gene (51) , and the phosphoenolpyruvate carboxykinase gene (19) , have been found to be activated by COUP-TFs. In an in vitro system, transactivation by ARP-1/ COUP-TFII has been observed (37) . Recently, Marcus and coworkers discovered that p62, a ligand for the tyrosine kinase signalling molecule p56 lck , interacts with COUP-TFII, possibly serving as a coactivator (40) . Thus, it has been suggested that the effect of COUP-TFs on transcriptional activity depends on organization of the DNA binding site, promoter architecture, and cell context (37, 51) .
Proteins of the COUP-TF family are among those members of the nuclear receptor superfamily which have been most highly conserved during evolution. The overall sequence identity between human COUP-TFI and its homolog in zebrafish, the sevenup 44 protein, for example, is as high as 96.4% (15) . Such a high degree of evolutionary conservation of the COUP-TF proteins strongly argues for an important biological function. It has been suggested that proteins of the COUP-TF family are involved in modulating the retinoic acid receptor (RAR)-and retinoid X receptor (RXR)-mediated responses to retinoids during embryogenesis (15, 57) . In Drosophila, zebrafish, and mouse, proteins of the COUP-TF family most likely play an important role in the development of the central nervous system and the eye (15, 44, 52) . COUP-TFs are also involved in muscle differentiation (45) and in development of the fat body in Drosophila (22) . Members of the COUP-TF family preferentially form homodimers and bind to a wide variety of response elements, which are recognized by other members of the superfamily (11) . Studies of members of the COUP-TF family in differentiated mammalian cells provide evidence for a role of these proteins in modulating transcriptional regulation of multiple genes by retinoid receptors (6, 55, 58) , hepatocyte nuclear factor 4 (HNF-4) (17, 25, 41) , vitamin D 3 receptor (10, 11) , thyroid hormone receptor (TR) (10, 11) , or peroxisome proliferator-activated receptor (43) .
Human ARP-1/COUP-TFII is a protein of 414 amino acids containing a DNA binding domain (DBD) with two zinc fingers of the four-cysteine type (residues 79 to 144) and a putative ligand binding domain (LBD) comprising residues 195 to 414 (26) . These two domains are separated by a flexible hinge region spanning residues 145 to 195. The hinge region has recently been found to be essential for interaction of the unliganded TR and the RAR with nuclear corepressor proteins (53, 59) . If the structure of the carboxy terminus of ARP-1/ COUP-TFII resembles the crystal structures of other nuclear receptors, which have been solved recently (7, 53, 59) , it can be assumed that it is formed by 11 helices interrupted by several loops (66) . The segment corresponding to helix 2 (H2) of other nuclear receptors is absent in the structure of the LBD of ARP-1/COUP-TFII. The hydrophobic core of the carboxyterminal domain is composed of H3 to H5, H8, H9, and the loops between H3 and H4 and between H8 and H9. The first residue of H3 corresponds to Ile206 in ARP-1/COUP-TFII. The ninth heptad repeat, which is essential for dimerization of other nuclear receptors, comprises residues 363 to 370 of H10.
The extreme carboxy termini of numerous nuclear hormone receptors harbor a highly conserved motif, the AF-2 AD core domain, corresponding to H12 (residues 394 to 401 in ARP-1/COUP-TFII) (5, 12, 14, 56, 68) . This domain serves an important function for both transactivation and release of corepressor proteins in the cases of TR and RAR (4, 38, 66) . Both functions depend on the presence of a ligand. Several potential coactivator proteins, which are able to interact with AF-2 domains of various nuclear receptors in a ligand-dependent fashion, and two putative corepressors contacting the hinge regions of TR and RAR have been identified (8, 9, 21, 28, 29, 46) . Recently Downes and coworkers reported that integrity of the E region of Rev-erbA␣ is essential for its interaction with N-CoR/RIP13 (13) .
The carboxy-termini of COUP-TFs have been defined as the active repression domain by several investigators (6, 10, 18, 31) . Ge and coworkers reported that the amino terminus of ARP-1/COUP-TFII harbors a second domain capable of repressing transcriptional activity of the human apo-AI gene promoter (18) . The mechanism of repression by COUP-TFs has been studied in some detail. Cooney and coworkers previously suggested that COUP-TFI is able to repress transcription by multiple mechanisms, including passive repression, active repression, and sequestration of RXR, the heterodimeric partner of several members of the nuclear hormone receptor superfamily (10) . The last mechanism is independent of DNA binding, while both passive and active repression require DNA binding of COUP-TFs. More recently, Leng and coworkers demonstrated that COUP-TFI is able to decrease transcriptional activity by active repression and by transrepression (31) . Based upon their results, those authors suggested that the repression domain of COUP-TFI is recruited to DNA by heterodimerization with RXR or other members of the nuclear receptor superfamily. Those authors found that the segment of the COUP-TFI protein comprising residues 155 to 408, corresponding to residues 148 to 401 of ARP-1/COUP-TFII, conferred active repressor activity on a heterologous DBD (31) . A truncated variant of COUP-TFI, in which residues 409 to 423, corresponding to residues 402 to 414 of ARP-1/COUP-TFII, had been deleted, however, failed to transrepress transcriptional activity in their studies.
A detailed mapping of functional domains of COUP-TFs involved in DNA-binding-dependent and -independent mechanisms of repression, however, has not been performed. Therefore, we have now proceeded to define the domains of ARP-1/COUP-TFII responsible for both its active repressor and transrepressor activities by conducting a thorough deletion analysis of the protein. Our results demonstrate that the smallest domain conferring repressor activity on a heterologous DBD comprises residues 210 to 414 of the protein. This domain does not coincide with the region of the protein required for transrepression, which comprises residues 193 to 399. This region of ARP-1/COUP-TFII is homologous to the segment encompassing H3 to H12 of other nuclear receptors (7, 53, 59, 66) . Despite the fact that DNA binding is not required for transrepressor activity, the presence of the DBD was found to be essential for transrepression, strongly suggesting that this domain not only is essential for DNA binding but also is critically involved in transrepression.
MATERIALS AND METHODS
Plasmid construction. All plasmids were constructed by standard cloning procedures. Restriction sites for XhoI and XbaI were introduced in plasmid pMT2-ARP-1 (kindly provided by G. Ginsburg) upstream and downstream of the ARP-1/COUP-TFII cDNA, respectively, to allow for subsequent cloning steps. Carboxy-terminally truncated variants of ARP-1/COUP-TFII were generated by digestion of the modified plasmid, previously cut by XbaI, with nuclease BAL 31. After addition of XbaI linkers, the plasmids were religated. The truncated cDNA was liberated by digestion with XhoI and XbaI and reinserted into plasmid pMT2, which had been cut with XhoI and XbaI. Some of the carboxyterminally truncated variants were generated by PCR with appropriate primer pairs containing restriction sites for XhoI and XbaI. Internal deletions of the ARP-1/COUP-TFII cDNA were generated by using two overlapping PCR fragments as described by Higuchi (20) . To generate the plasmid Inf-ARP-1/COUP-TFII, a double-stranded oligonucleotide containing the coding sequence for a 15-amino-acid peptide tag (Inf-tag [see Fig. 3 to 5]) was inserted into plasmid pMT2, which was previously cut with XhoI and XbaI. The resulting plasmid was designated Inf-pMT2. The oligonucleotide contained an additional in-frame cutting site for DraIII immediately upstream of the XbaI site. This permitted subsequent insertion of a PCR fragment containing the coding sequence for ARP-1/COUP-TFII into the DraIII and XbaI sites, to generate plasmid Inf-ARP-1/COUP-TFII. Amino-terminally truncated variants, carboxy-terminally truncated variants, and variants lacking internal domains of the Inf-modified protein were generated by PCR. Plasmid Ϫ139CAT, containing the fragment extending from position Ϫ139 to ϩ121 of the human apo-B promoter region, has been described previously (47) . To generate plasmid pMT2-GAL-DBD, the segment of the GAL4 cDNA encoding amino acids 1 to 147 was amplified by PCR with a sense primer containing a SalI site and an antisense primer containing binding sites for DraIII and XbaI. After digestion with SalI and XbaI, the fragment was inserted into plasmid pMT2 which had been previously cut with XhoI and XbaI. Various PCR-amplified fragments of the carboxy terminus of ARP-1/COUP-TFII tagged with DraIII and XbaI sites were the inserted in frame into plasmid pMT2-GAL-DBD which had been digested with the restriction enzymes DraIII and XbaI. Chimeric proteins in which the amino-terminal part of ARP-1/COUP-TFII was fused to the carboxy terminus of HNF-4 were generated by PCR as described by Higuchi (20) . In plasmid HNF-3 TATA-CAT, six copies of the HNF-3 binding site of the apo-B gene promoter (positions Ϫ106 to Ϫ95) were inserted into an XbaI site upstream of a minimal apo-B promoter fragment extending from position Ϫ30 to ϩ121 in a CAT plasmid. In construct C/EBP TATA-CAT, six copies of the C/EBP binding site from the apo-B promoter (positions Ϫ72 to Ϫ53) were placed upstream of the minimal apo-B promoter fragment, while construct apoB TATA-CAT contained six copies of the binding site for HNF-4 from the apo-B promoter (positions Ϫ86 to Ϫ62) and construct apoA TATA-CAT contained five copies of the HNF-4 binding site from the apo-AI promoter (positions Ϫ214 to Ϫ192). In plasmid Sp1 TATA-CAT, three copies of the canonical Sp1 binding site 5Ј-GGGGCGGG-3Ј were placed upstream of the minimal apo-B promoter fragment; in plasmid ATF TATA-CAT, five copies of an ATF binding site from the human fibronectin gene promoter (positions Ϫ161 to Ϫ176) were inserted upstream of the minimal apo-B promoter fragment (63) . In plasmid apoBmut(Ϫ139 to ϩ121), the binding site for HNF-4 within the apo-B promoter (positions Ϫ86 to Ϫ62) was replaced by a recognition site for HNF-3 by PCR-mediated mutagenesis (20) . The integrity and correctness of all plasmids were verified by DNA sequencing. Details about PCR primers and cloning strategies used to generate the various constructs used in the experiments described throughout this paper are available upon request.
Tissue culture and transient-transfection experiments. Human colon carcinoma cells (CaCo-2) were grown in minimal essential medium supplemented with 15% fetal calf serum as described previously (49) . HepG2 cells were cultured in minimal essential medium supplemented with 10% fetal calf serum. Approximately 24 h prior to transfection, confluent cultures were trypsinized, and about 4 ϫ 10 6 to 5 ϫ 10 6 cells were seeded in a T75 flask. In a typical experiment, cells were cotransfected by using a calcium phosphate coprecipitation protocol (19) with 10 g of chloramphenicol acetyltransferase (CAT) plasmid, 5 g of the internal reference plasmid pSV-␤Gal (Promega Corporation, Madison, Wis.), and 5 g of an expression plasmid for ARP-1/COUP-TFII (pMT2-ARP-1) (26) or for one of its variants. In each experiment the total amount of plasmid DNA was adjusted to 20 g. In transient-transfection experiments, relative transcriptional activities of the various CAT constructs compared to the activity of the apoB(Ϫ139 to ϩ121) CAT construct, which was set at 100%, were as follows: apoB TATA-CAT uninduced, 8.5%; apoB TATA-CAT induced by pBJ5-HNF-4, 40%; apoB TATA-CAT induced by pMT2-ARP174 HNF-4, 48%; apoA TATA-CAT uninduced, 2.5%; apoA TATA-CAT induced by pBJ5-HNF-4, 75%; apoA TATA-CAT induced by pMT2-ARP174 HNF-4, 92%; TATA-CAT uninduced, 0%; TATA-CAT induced by TATA binding protein (TBP), 5%; apoBmut(Ϫ139 to ϩ121) CAT, 12.5%; 17-mer apoB(Ϫ139 to ϩ121) CAT, 55%; HNF-3 TATA-CAT, 5%; C/EBP TATA-CAT, 7%; Sp1 TATA-CAT, 15%; ATF TATA-CAT, 10%; 17-mer TATA-CAT uninduced, 0%; 17-mer TATA-CAT induced by TBP, 5%; 17-mer TATA-CAT induced by pMT2-GAL-DBD-HNF-4(147 to 455), 20%.
Gel mobility shift assays and preparation of whole-cell extracts. For preparation of whole-cell extracts, Cos cells were transfected with 20 g of expression plasmids for ARP-1/COUP-TFII or for one of its mutant forms by using the calcium phosphate coprecipitation technique. Approximately 48 h after transfection, cells were harvested. The cell pellet from one T75 tissue culture flask was resuspended in 50 l of a buffer consisting of 20 mM Tris-HCl (pH 7.9), 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol. Subsequently, cells were disrupted by three cycles of freeze-thawing. After the cell debris was pelleted for 10 min at 4°C in a microcentrifuge, the supernatant was snap-frozen on dry ice and stored at Ϫ70°C in small aliquots. For gel mobility shift assays, 3 l of nuclear extract was incubated for 30 min with 1 ng of a 32 P-labeled double-stranded oligonucleotide and 4 g of poly(dI-dC) in a buffer containing 15 mM HEPES (pH 7.9), 15% glycerol, 0.6 mM EDTA, 60 mM KCl, 5 mM MgCl 2 , and 0.6 mM dithiothreitol. Incubation mixtures were subsequently fractionated on 4.9% polyacrylamide gels (acrylamide-bisacrylamide, 40:0.5) in 0.5ϫ Tris-borate-EDTA. After running, gels were soaked in 10% glycerol for 10 min-vacuum dried, and exposed to X-ray films (Kodak X-OMAT AR ). Synthesis of oligonucleotides. Oligonucleotides for PCR, cloning, or gel mobility shift assays were synthesized on a Cyclone Plus DNA synthesizer (MilligenBiosearch, Burlington, Mass.) or purchased from MWG-Biotech GmbH (Munich, Germany). All oligonucleotides were desalted on NAP-10 columns (Pharmacia Biotech AB, Uppsala Sweden). Pairs of complementary singlestranded oligonucleotides used in gel mobility shift assays or for cloning procedures were annealed, purified on nondenaturing 12 to 15% acrylamide gels, and electroeluted by using Spectrapor 3 dialysis tubing (Spectrum Medical Industries, Inc., Los Angeles, Calif.) in 0.1ϫ Tris-borate-EDTA buffer.
Indirect immunofluorescence. Approximately 24 h after transfection, Cos cells were trypsinized and seeded into Leighton tubes (Corning Costar Corporation, Cambridge, Mass.). Twenty-four hours later, medium was removed and cells were rapidly fixed in 4% formalin in phosphate-buffered saline (PBS) (pH 7.4) for 15 min. Subsequently, the slides were thoroughly washed in PBS for 30 min. Indirect immunofluorescence was performed with a biotin-streptavidin-Texas red system. Cells were exposed to a blocking reagent containing 10% nonimmune normal goat serum, 0.1% bovine serum albumin, and 1% Triton X-100 in PBS (pH 7.4) for 1 h at room temperature. Subsequently, cells were incubated overnight at 4°C with the mouse monoclonal anti-AH antibody 12CA5 (Boehringer Mannheim Corporation, Indianapolis, Ind.) at a final concentration of 1 g/ml. After thorough rinsing with PBS, cells were exposed to the secondary biotinylated antimouse antibody (Amersham International, Buckinghamshire, England) at a final dilution of 1:50 for 1 h at room temperature. The secondary antibody was diluted in PBS (pH 7.4) containing 0.1% bovine serum albumin and 0.1% Triton X-100. Cells were then rinsed in PBS and incubated with streptavidin-Texas red (Amersham International) at a dilution of 1:50. Finally, the slides were washed in PBS and mounted in Glycergel medium (Dakopatts, DK). To obtain information about the level of expression of the various mutant proteins, the following strategy was employed. In a first step, the threshold level of expression at which the wild-type ARP-1/COUP-TFII protein can be detected by indirect immunofluorescence was determined. To this end, Cos cells were transfected with decreasing amounts of expression plasmid (10.0, 5.0, 2.5, 1.0, 0.5, and 0.25 g). Protein expression was subsequently analyzed by indirect immunofluorescence. The efficiency of transient transfections was verified by cotransfection with an expression plasmid for beta-galactosidase (RSV-␤Gal). In Cos cells transfected with 10.0, 5.0, or 2.5 g, the protein could be readily detected by indirect immunofluorescence, while expression could not be visualized in Cos cells transfected with smaller amounts of expression plasmids, indicating that the threshold for detection of protein expression by indirect immunofluorescence lies between 2.5 and 1.0 g. To verify that all mutants were expressed at a level comparable to or exceeding the level observed with 2.5 g of the ARP-1/COUP-TFII expression plasmid, Cos cells were transiently transfected with 2.5 g of expression plasmids for the various mutant proteins. In these experiments each of the mutants could be detected by indirect immunofluorescence in transfected cells.
RESULTS
The presence of the AF-2 AD core domain is essential for repressor activity of ARP-1/COUP-TFII. To map functional domains of ARP-1/COUP-TFII, we conducted a thorough deletion analysis of the protein. In a first set of experiments, a series of carboxy-terminally truncated variants of the protein was tested for repressor activity. The ability of mutant proteins to suppress transcriptional activity of the human apo-B gene promoter was used to define domains of the protein required for repressor activity. A plasmid in which the CAT gene is driven by the human apo-B promoter fragment extending from position Ϫ139 to ϩ121 (Ϫ139CAT) (49) was employed as a reporter construct in these experiments (Fig. 1A) . The results are summarized in Fig. 1B . The wild-type ARP-1/COUP-TFII protein repressed transcriptional activity of the human apo-B gene about 50-fold. Deletion of residues 399 to 414 did not significantly alter repressor activity, indicating that this domain is not required for repressor activity. Removal of residues 395 to 414, however, almost completely abolished repressor activity, clearly demonstrating that residues 395 to 399 are crucial for repressor activity of ARP-1/COUP-TFII. These residues constitute the central part of a domain that is homologous to the AF-2 AD core in other members of the nuclear receptor superfamily (66) . Mutants 383, 373, 369, and 324 also failed to repress transcription to a significant extent. Mutant 302, however, decreased activity of the apo-B gene promoter about fourfold, and mutant 240 decreased activity about fivefold. Surprisingly, mutants 213 and 194 exhibited considerable repressor activity (about 11-fold and 16-fold, respectively), while mutant 174 repressed transcriptional activity approximately 5-fold. These results suggest the existence of a domain with repressor activity in the region between residues 174 and 194.
By using gel mobility shift assays, DNA binding of the truncated proteins was analyzed (Fig. 2 ). In these experiments the ARP-1/COUP-TFII recognition site of the human apo-AI promoter (positions Ϫ214 to Ϫ192) (26) was used as a labeled probe. Similar results were obtained in gel mobility shift assays in which the apo-B site, which represents a weaker binding site for ARP-1/COUP-TFII than the apo-AI site (see Fig. 6 ), was used as a probe (data not shown).
The presence of the DBD and carboxy terminus is required for repressor activity of ARP-1/COUP-TFII, while the amino terminus and hinge region are dispensable for repression. To further delineate domains required for repressor activity of ARP-1/COUP-TFII, mutant proteins lacking internal or amino-terminal domains were tested in transient-transfection experiments (Fig. 3) . To allow for detection of the mutant proteins by indirect immunofluorescence, the 12CA5 epitope from the influenza virus hemagglutinin protein (Inf tag) was attached to the amino terminus of the mutant proteins. DNA binding of the mutant proteins was examined in gel mobility shift assays. The results of these experiments are summarized in Fig. 3 . Deletion of the carboxy-terminal portion of the DBD (residues 131 to 144) resulted in complete loss of repressor activity and DNA binding. Deletion of residues 145 to 159, corresponding to the carboxy-terminal extension domain (30) , resulted in a mutant which was unable to bind to DNA but repressed transcriptional activity to the same extent as the wild-type protein. Similar results were obtained with a mutant in which residues 145 to 192 were deleted. Deletion of the segment comprising residues 145 to 209 resulted in a mutant which lacked both DNA binding and repressor activity. From this result it can be concluded that residue 193 represents the amino-terminal boundary of the repression domain. Mutants ⌬145-159, ⌬145-192, and ⌬145-414 were found exclusively in CAT activities (act.) (Ϯ standard deviations) are expressed relative to that of the Ϫ139CAT construct cotransfected with an empty control plasmid, which was set at 100%. Numbers in parentheses represent the number of independent transfections performed for each construct. Asterisks mark constructs whose nuclear localization was verified by indirect immunofluorescence. DNA binding of wild-type and mutant ARP-1/COUP-TFII proteins as assessed in gel mobility shift assays, in which the ARP-1/COUP-TFII recognition site of the human apo-AI promoter (sequence Ϫ214 to Ϫ192) was used as a labeled probe, is indicated by ϩ (DNA binding), (ϩ) (weak DNA binding), or Ϫ (no DNA binding). the nucleus, while mutant ⌬145-209 was detected only in the cytoplasmic compartment, indicating that residues 193 to 209 play a crucial role for nuclear translocation of the protein.
Alternatively, global conformational changes may explain the discrepancy in subcellular localization of mutant ⌬145-209, which was found exclusively in the cytoplasm, and mutant ⌬145-414, which was detected exclusively in the nucleus. Changes in protein conformation may also contribute to the loss of repressor activity of mutant ⌬145-209.
The results obtained with carboxy-terminally truncated variants of the protein suggest that the region between residues 174 and 194 may contain a domain with repressor activity (Fig.  1) . To examine the role of this region in repressor activity, a mutant lacking residues 160 to 192 was generated. This deletion did not significantly alter repressor activity, nor did it affect DNA binding, suggesting that in the context of the intact protein this domain does not contribute to repressor activity. Removal of the amino terminus (residues 1 to 77) did not affect repressor activity. Deletion of residues 1 to 92, however, resulted in complete loss of DNA binding accompanied by loss of repressor activity. The amino terminus did not exhibit any repressor activity on its own. Similarly, a mutant lacking the entire carboxy terminus (residues 145 to 414) failed in repressing transcription and binding to DNA. In conclusion, these results demonstrate that the amino terminus and hinge region comprising residues 145 to 192 are dispensable for repressor activity, while the DBD (residues 79 to 144) and the E domain (residues 210 to 399) are required for repression.
Integrity of the ninth heptad repeat is essential for repressor activity of ARP-1/COUP-TFII. From the recently published crystal structure of RXR␣ (7), it is evident that the ninth heptad repeat in H10 constitutes an essential portion of the dimerization interface. To evaluate the importance of the ninth heptad repeat for repressor activity of ARP-1/COUP-TFII, several point mutations were introduced within this domain. Functional activities, DNA binding properties, and subcellular localization of the resulting mutants are summarized in Fig. 4 . The ARP-1/COUP-TFII recognition site from the apo-AI gene promoter was used as a labeled probe to examine the DNA binding properties of these mutants. Replacement of arginine 366 by glycine did not alter repressor activity, nor did it affect DNA binding. Similar results were observed with a mutant in which leucine 367 was replaced by phenylalanine. The simultaneous introduction of three amino acid substitutions (Leu363Arg, Leu364Ser, and Leu367Phe), however, significantly impaired both DNA binding and repressor activity. This result demonstrates that integrity of the ninth heptad repeat is essential for both repressor activity and DNA binding of ARP-1/COUP-TFII.
Despite the fact that several mutants deficient in DNA binding efficiently repressed transcriptional activity (Fig. 3) , loss of repressor activity of mutants lacking parts of the DBD (Fig. 3 ) strongly suggests that the presence of the DBD is a strict requirement for repressor activity of the protein. This finding provides evidence that the DBD not only is essential for DNA binding but also serves a function for repressor activity. To further pursue this question, P-box residues of ARP-1/COUP-TFII were replaced by the corresponding residues of the glucocorticoid receptor. The mutant containing these amino acid substitutions was unable to bind to the ARP-1/COUP-TFII recognition site from the apo-B gene promoter but nevertheless repressed transcriptional activity to a significant extent, further confirming the proposed hypothesis.
Residues 210 to 414 define the minimal active repression domain of ARP-1/COUP-TFII. Several studies have demonstrated that the carboxy termini of COUP-TFs represent a transferable active repression domain (6, 10, 18, 31) . To map the boundaries of this domain of ARP-1/COUP-TFII, various segments of its carboxy terminus were fused to the GAL4 DBD. The GAL4 DBD, comprising residues 1 to 147 of the protein, contains a nuclear localization signal as well as a dimerization domain, thus eliminating possible interpretation problems with ARP-1/COUP-TFII mutations affecting these functions. Transcriptional activity of the fusion proteins was assessed by using a reporter construct in which two copies of the binding site for GAL4 (17-mer) were inserted upstream of the apo-B promoter fragment (Fig. 5A) . The results of these experiments are summarized in Fig. 5B . When fused to the GAL4 DBD, the entire carboxy terminus repressed transcriptional activity of the reporter construct by about eightfold. Transcriptional activity of the apo-B promoter CAT construct lacking GAL4 binding sites, however, was not affected by the fusion protein (data not shown).
In agreement with the results obtained with the wild-type ARP-1/COUP-TFII protein, deletion of the extreme carboxy terminus containing the AF-2 AD core (residues 395 to 414) resulted in complete loss of repressor activity. The fusion protein lacking this domain even slightly increased transcriptional activity of the reporter construct. Deletion of residues 145 to 192 of the carboxy terminus did not affect repressor activity of the fusion protein. Repressor activity was also unaltered when the deletion was expanded to comprise residues 145 to 209. Deletion of residues 145 to 231, however, resulted in a complete loss of repressor activity. Fusion proteins containing the segment spanning residues 266 to 414 or 377 to 414 also lacked repressor activity. To define the carboxy-terminal boundary of the active repression domain, the segment comprising residues 210 to 399 was fused to the GAL4 DBD. This domain failed to function as a transferable repressor module.
To examine the functional importance of various internal FIG. 3 . Effects of internal and terminal deletions on repressor activity of ARP-1/COUP-TFII. The effects of various internal and terminal deletions of ARP-1/ COUP-TFII on repressor activity were tested as described in the legend to Fig. 1 . Wild-type and variant proteins are shown diagramatically on the right. All proteins used in these experiments were tagged with the 12CA5 epitope from the influenza virus hemagglutinin (Inf tag). CAT activities of the reporter construct (Ϫ139CAT) obtained in cotransfection assays with the wild-type and various mutant proteins, subcellular localization (Subcell. localiz.) of the proteins as determined by indirect immunofluorescence, and results of gel mobility shift assays are summarized on the left. The ARP-1/COUP-TFII recognition site from the apo-AI gene promoter (sequence Ϫ214 to Ϫ192) was used as a labeled probe in gel mobility shift assays. CAT activities (act.) (Ϯ standard deviations) are expressed relative to that of the Ϫ139CAT construct cotransfected with an empty control plasmid, which was set at 100%. Numbers in parentheses represent the number of independent transfections performed for each construct. nucl., nucleus; cytopl., cytoplasm.
segments of the carboxy-terminal repression domain, four mutants containing different internal deletions (⌬160 to 250 [H1 to H5], ⌬160 to 350 [H1 to H9], ⌬251 to 349 [H6 to H9], and ⌬357 to 392 [H10 and H11]) were generated. None of these constructs was able to repress transcriptional activity of the reporter construct, clearly demonstrating that integrity of the domain encompassing residues 210 to 399 (H3 to H10) is a prerequisite for active repressor activity. The domain comprising residues 210 to 414 can thus be considered the minimal active repression domain of ARP-1/COUP-TFII. This domain does not coincide with the segment of the carboxy terminus involved in repressor activity of the wild-type ARP-1/COUP-TFII protein, which encompasses residues 193 to 399.
Attachment of the nuclear localization signal of the SV40 large T antigen to the amino terminus of ARP-1/COUP-TFII abolishes DNA binding but not repressor activity. Some of the mutant proteins displayed in Fig. 3 were defective in nuclear translocation. To exclude the possibility that this defect was responsible for the impaired repressor activity observed with some of these mutants, the strong nuclear localization signal from the simian virus 40 (SV40) large T antigen was attached to the amino termini of wild-type and mutant proteins in front of the Inf tag. Nuclear localization of the modified proteins was verified by indirect immunofluorescence.
In both HepG2 and CaCo2 cells, the Flu-modified protein repressed transcriptional activity to the same extent as the wild-type and the Inf-tagged proteins (Fig. 6) . The repressor activity of all three proteins was consistently more pronounced in CaCo2 cells than in HepG2 cells. Surprisingly the Flu-modified ARP-1/COUP-TFII protein failed to bind to its cognate site within the apo-B gene promoter, a DR2 element. Binding to the ARP-1/COUP-TFII recognition site from the human apo-CIII gene promoter, a DR1 element, was also abolished by attachment of the Flu tag to the ARP-1/COUP-TFII protein, while binding of the modified protein to the recognition site from the human apo-AI promoter, to which the unmodified protein bound with the highest affinity, was strongly reduced. At present the mechanism by which the Flu tag interferes with DNA binding is unclear. Positively charged amino acids within the peptide tag, possibly interacting with cysteine residues of the DBD, may play a role. The Inf-tagged protein was able to bind to all three recognition sites. Addition of an antibody directed against the hemagglutinin epitope resulted in a marked supershift of the retarded complex obtained with the Inf-tagged protein. The antibody, however, failed to recognize the Flu-tagged protein in this assay.
Failure of the Flu-modified protein to bind to its cognate site within the apo-B gene promoter in a gel mobility shift assay contrasts with its unaltered repressor activity in transienttransfection assays. This discrepancy may indicate that the Flu-modified protein is able to bind to its recognition site under conditions of a living cell, while it fails to bind to this sequence in an in vitro assay. To further investigate this issue, chimeric proteins in which the carboxy-terminal activation domain of HNF-4 is fused to the amino terminus of ARP-1/ COUP-TFII or the Flu-modified variant were generated (Fig.  7A) . Transcriptional activities of the fusion proteins were examined in transient-transfection assays with reporter CAT constructs in which several copies of the binding site for ARP-1/COUP-TFII of the apo-AI or the apo-B promoter were placed upstream of a minimal apo-B promoter fragment (Fig.  7B) . The fusion protein induced transcriptional activity of the apoA TATA construct about 36-fold, while activity of the apoB TATA construct was induced approximately 6-fold. The Flu -FIG. 4 . Effects of amino acid substitutions within the ninth heptad repeat or the DBD on repressor activity of ARP-1/COUP-TFII. The effects of amino acid substitutions within the ninth heptad repeat or the DBD on repressor activity of ARP-1/COUP-TFII were examined as described in the legend to Fig. 1 . Diagrams of the mutant proteins are presented on the right. Results of CAT assays, gel mobility shift assays, and indirect immunofluorescence are summarized on the left. The ARP-1/COUP-TFII recognition site from the apo-AI gene promoter (sequence Ϫ214 to Ϫ192) was used as a labeled probe in gel mobility shift assays. CAT activities (act.) (Ϯ standard deviations) are expressed relative to that of the Ϫ139CAT construct cotransfected with an empty control plasmid, which was set at 100%. Numbers in parentheses represent the number of independent transfections performed for each construct. Subcell. localiz., subcellular localization; nucl., nucleus; cytopl., cytoplasm.
FIG. 5. Characterization of the active repression domain of ARP-1/COUP-TFII. (A)
Diagram of the reporter construct which was used to define the minimal repression domain of ARP-1/COUP-TFII. In the reporter construct, two copies of the 17-mer binding site for GAL4 were inserted upstream of the segment Ϫ139 to ϩ121 of the human apo-B gene promoter. (B) Diagrams of GAL4 ARP-1/COUP-TFII proteins cotransfected with the reporter construct are shown on the right. CAT activities of the reporter construct obtained in cotransfection experiments with various fusion proteins are summarized on the left. CAT activities (act.) (Ϯ standard deviations) are expressed relative to that of the 17-mer apoB(Ϫ139 to ϩ121) CAT construct cotransfected with an expression plasmid for the GAL4 DBD, which was set at 100%. Numbers in parentheses represent the number of independent transfections performed for each construct.
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on February 23, 2013 by PENN STATE UNIV http://mcb.asm.org/ modified variant increased transcriptional activity of the apo-AI construct about eightfold, while it failed to induce activity of the apo-B construct (Fig. 7A) . DNA binding of the chimeric proteins is shown in Fig. 7C . The unmodified fusion protein and a mutant of the protein truncated at residue 174 bound to both the apo-B and the apo-AI sites. The Flu-tagged proteins failed to bind to the apo-B site, while they exhibited low-affinity binding to the recognition site of the apo-AI promoter. These results confirm that attachment of the Flu tag results in loss of DNA binding not only in a gel mobility shift assay, an in vitro experiment, but also under the conditions of a living cell.
Having established that the Flu-modified ARP-1/COUP-TFII protein fails to bind to the apo-B site, we asked whether this mutant is able to repress transcriptional activity of the apoB TATA-CAT construct induced by HNF-4. To address this question, CaCo-2 cells were cotransfected with the apoB TATA-CAT reporter construct, with a constant amount of an HNF-4 expression plasmid and with various amounts of an expression plasmid for either the Flu-modified or the wild-type ARP-1/COUP-TFII protein. As demonstrated in Fig. 8 , both the mutant and the wild-type proteins repressed transcriptional activity to the same extent at all concentrations tested. This result strongly supports the hypothesis that transrepression is the predominant mechanism underlying repressor activity by ARP-1/COUP-TFII.
The domains of ARP-1/COUP-TFII required for active repression and transrepression do not coincide. The observation that modification of the ARP-1/COUP-TFII protein by the Flu tag abolished binding of the protein to its cognate site within the apo-B gene promoter without affecting its repressor activity enabled us to determine which domains of the protein are required for its transrepressor activity. To this end, a series of Flu-tagged deletion mutants was generated and tested for repressor activity in transient-transfection experiments using the apo-B promoter CAT construct as a reporter. All mutants failed to bind to the apo-B recognition site in gel mobility shift assays. The domains required for transrepressor activity of the Flu-modified protein were identical to the domains which had been found to be essential for repressor activity of the unmodified or the Inf-tagged protein (data not shown). They include the DBD and the segment comprising residues 193 to 399. Unlike mutant ⌬145-209 lacking the Flu-tag, which is located entirely in the cytoplasmic compartment (Fig. 3) , the corresponding Flu-modified variant was detected exclusively in the nucleus (data not shown). Like the Inf-tagged protein, the Flu-modified protein failed to repress transcriptional activity, demonstrating that residues 193 to 209 are essential not only for nuclear localization but also for transrepressor activity of the protein. Internal deletions within the carboxy terminus of the protein (⌬160-349, ⌬160-250, ⌬251-349, and ⌬357-391) abolished repressor activity (data not shown), indicating that integrity of this domain is crucial for transrepressor activity. In conclusion, these experiments reveal the DBD and the segment of the carboxy terminus encompassing residues 193 to 399 as the minimal transrepression domain of ARP-1/COUP-TFII. This domain does not coincide with the domain required for active repression (Fig. 5) . These results strongly suggest that transrepression, rather than active repression, is the predominant mechanism underlying repression of apo-B promoter activity by ARP-1/COUP-TFII.
Transcriptional repression of the human apo-B gene promoter by ARP-1/COUP-TFII does not depend on the presence of its cognate DNA binding site (positions ؊86 to ؊62). The transcriptional activity of the human apo-B gene promoter is induced by the synergistic action of various transactivator proteins binding to sequences within the proximal promoter region. The sequence Ϫ86 to Ϫ62 represents a binding site for members of the nuclear receptor superfamily, including HNF-4 and COUP-TFs. HNF-3 binds to the sequence Ϫ95 to Ϫ106, while the sequence Ϫ72 to Ϫ53 is recognized by proteins of the C/EBP family. The observation that DNA binding is not required for repressor activity of ARP-1/COUP-TFII prompted us to ask whether the presence of the COUP-TF binding site within the proximal promoter (positions Ϫ86 to Ϫ62) is essential for repression of apo-B promoter activity by the orphan receptor. To address this question, the ARP-1/COUP-TFII binding site within the apo-B gene promoter was converted to a recognition site for HNF-3 by introduction of six base substitutions (Fig.  9A) . In gel mobility shift assays, DNA binding of the mutant sequence was examined. The sequence failed to recognize HNF-4 or ARP-1/COUP-TFII but bound HNF-3␣ with high affinity (data not shown). Transcriptional activity of a CAT construct driven by the mutant apo-B promoter was about eightfold lower than activity of the wild-type construct. Despite the absence of its cognate binding site, however, overexpression of the unmodified or the Flu-modified ARP-1/COUP-TFII protein resulted in about a 10-fold suppression of transcriptional activity of the mutant promoter by ARP-1/COUP-TFII (Fig. 9B) . These results clearly demonstrate that repression of the human apo-B gene promoter by ARP-1/ COUP-TFII does not depend on the presence of its recognition site within the proximal promoter region.
Transcriptional activation mediated by sequences ؊86 to ؊62, ؊72 to ؊53, and ؊106 to ؊95 of the human apo-B gene promoter is repressed by ARP-1/COUP-TFII, while basal transcription or transactivation induced by Sp1 or ATF is not perturbed by ARP-1/COUP-TFII. To define the sequences within the apo-B gene promoter region which are targets for repression by ARP-1/COUP-TFII, three artificial promoter CAT constructs were generated, in which several copies of the binding site for either HNF-3, C/EBP, or HNF-4 were inserted upstream of a minimal apo-B promoter fragment (Fig. 10A ). This promoter fragment by itself (positions Ϫ30 to ϩ121) was unable to induce transcriptional activity. Insertion of binding sites for various transactivators resulted in an increase in promoter activity. The promoter activities of all three constructs were repressed to a similar extent by overexpression of the unmodified or the Flu-modified ARP-1/COUP-TFII protein.
In gel mobility shift assays, binding of ARP-1/COUP-TFII or of the Flu-modified variants to any of these sequences could be excluded (data not shown). It cannot be excluded, however, that repression of transcriptional activity of constructs lacking the recognition site (positions Ϫ86 to Ϫ62) might be explained by the presence of a cryptic ARP-1/COUP-TFII binding site between positions Ϫ53 and ϩ121. The existence of such a binding site, however, would not explain the observed repression of the various constructs by the Flu-modified protein.
To test whether transcriptional activity induced by other transactivators, such as the ubiquitous factors Sp1 and ATF, is also repressed by ARP-1/COUP-TFII, artificial promoter CAT constructs containing several copies of a binding site for one of these proteins were generated. Overexpression of ARP-1/ COUP-TFII failed to repress transcriptional activity of these constructs (Fig. 10B) . Sp1-induced transcriptional activity was even increased twofold. In conclusion, these experiments demonstrate that ARP-1/COUP-TFII transrepresses transcrip- (Fig. 6) as a reporter. CaCo-2 cells were cotransfected with 5 g of the CAT plasmid, 2 g of an expression plasmid for HNF-4, and the indicated amount of an expression plasmid for wild-type or mutant ARP-1/COUP-TFII protein. CAT activities (with standard deviations) are expressed relative to that of the apoB TATA-CAT construct cotransfected with an empty control plasmid, which was set at 100%. Each CAT value represents the mean from at least two independent transfection experiments.
tional activity induced by certain transactivators, including liver-enriched proteins such as HNF-3, C/EBP, and HNF-4, but not that induced by others, such as the ubiquitous factors Sp1 and ATF.
To examine whether basal transcription is affected by ARP-1/COUP-TFII, transient-transfection experiments using a CAT construct containing the minimal apo-B promoter fragment extending from position Ϫ30 to ϩ121 were performed. This construct did not exhibit any promoter activity on its own. Cotransfection with an expression plasmid for TBP resulted in FIG. 9 . Effect of overexpression of ARP-1/COUP-TFII or Flu-ARP-1/COUP-TFII on transcriptional activity of a mutant apo-B gene promoter in which the sequence Ϫ86 to Ϫ62 was converted into a recognition site for HNF-3 by site-directed mutagenesis. (A) Diagrams of the wild-type and mutant apo-B promoter CAT construct illustrating the base changes within the ARP-1/COUP-TFII recognition site. (B) Effect of overexpression of ARP-1/COUP-TFII or Flu-ARP-1/COUP-TFII on transcriptional activity of the mutant apo-B promoter CAT construct. CAT activities of the apo-Bmut promoter construct in the presence of wild-type or mutant unmodified ARP-1/COUP-TFII proteins are summarized. CAT activities (with standard deviations) are expressed relative to that of the apoBmut promoter CAT construct cotransfected with an empty control plasmid, which was set at 100%. Each CAT value represents the mean from at least two independent transfection experiments.
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on February 23, 2013 by PENN STATE UNIV http://mcb.asm.org/ Downloaded from a significant increase in promoter activity which was not repressed by overexpression of ARP-1/COUP-TFII (Fig. 10C) . The same result was obtained when a construct containing several copies of a binding site for GAL4 upstream of the minimal promoter fragment (17-mer TATA-CAT) was cotransfected with TBP and a fusion protein between the GAL4 DBD and the carboxy terminus of ARP-1/COUP-TFII (Fig.  10C ). These results demonstrate that ARP-1/COUP-TFII is not able to repress basal transcription, either by transrepression or by active repression. Recently, Leng and coworkers (31) demonstrated that COUP-TFI represses transcriptional activity induced by fusion proteins between the GAL4 DBD and the LBD of TR, RXR, or RAR. Based upon these results, they proposed a mechanism for transrepression by COUP-TFs involving heterodimerization of COUP-TF proteins with other nuclear hormone receptors, such as TR, RAR, or RXR. In similar experiments, we asked whether ARP-1/COUP-TFII is able to affect transcriptional activity induced by a fusion protein between the GAL4 DBD and the carboxy-terminal activation domain of HNF-4. As shown in Fig. 10C , a mutant of ARP-1/COUP-TFII truncated at residue 399 strongly repressed transcriptional activity induced by the GAL4 fusion. Identical results were obtained with the wild-type ARP-1/COUP-TFII protein (data not shown). Since HNF-4 has been found to form exclusively homodimers (23), it seems unlikely that formation of heterodimers between the GAL4-HNF-4 fusion protein and ARP-1/COUP-TFII contributes significantly to the repression observed in these experiments.
Overexpression of C/EBP␣ but not HNF-4, RXR␣, HNF-3␣, p300, or CPB results in relief of repression by ARP-1/COUP-TFII. In transient-transfection experiments, several transcription factors which may be involved in transcriptional activation of the human apo-B gene promoter were tested for their ability to relieve transcriptional repression mediated by ARP-1/ COUP-TFII. The results of these experiments are summarized in Fig. 11 . Overexpression of HNF4, RXR␣, HNF-3␣, p300, or CREB binding protein (CBP) did not relieve repression by ARP-1/COUP-TFII. Overexpression of C/EBP␣, however, significantly decreased the extent of repression, suggesting that this transactivator is able to induce transcriptional activity by a mechanism which is resistant to repression by ARP-1/COUP-TFII.
DISCUSSION
The domains of ARP-1/COUP-TFII involved in active repression and transrepression do not coincide. It has been suggested that transcriptional repression by COUP-TFs involves multiple mechanisms, including passive repression, active repression, and transrepression (10) . In the present study we defined the domains of the orphan receptor ARP-1/COUP-TFII that are required for active repression and transrepression of ARP-1/COUP-TFII. The results of the present study provide strong evidence that passive repression does not play a major role in repression by ARP-1/COUP-TFII, since several mutants which strongly bind to DNA fail to efficiently repress transcription.
The active repression domain was characterized by using chimeric proteins in which various segments of the ARP-1/ COUP-TFII carboxy-terminal repression domain were fused to the GAL4 DBD. The segment comprising residues 210 to 414 was found to confer repressor activity to a heterologous DBD. Repression of transcriptional activity of the apo-B gene promoter by the GAL4 fusion protein, however, was dependent on the presence of the GAL4 recognition site in the CAT plasmid, demonstrating that this protein was unable to function as a transrepressor.
Attachment of the nuclear localization signal of the SV40 large T antigen to the amino terminus of ARP-1/COUP-TFII completely abolished binding of the protein to its cognate site within the apo-B promoter without affecting its repressor activity. This finding allowed the characterization of domains responsible for transrepression by using a series of Flu-tagged variants of the protein. In these experiments the DBD and the segment comprising residues 193 to 399 could be defined as the portions of the protein required for transrepression. Recently, Leng and coworkers (31) reported that repressor activity of COUP-TFI involves different mechanisms, namely, active repression and transrepression. In their study the entire carboxy terminus of COUP-TFI was required for transrepression. Deletion of residues 423 to 409, corresponding to residues 414 to 402 of ARP-1/COUP-TFII, resulted in an almost complete loss of repressor activity. The domain of COUP-TFI required for active repression was found to extend to residue 408, which corresponds to leucine 401 in ARP-1/COUP-TFII. Our results are in striking disagreement with these findings, in that the minimal domain required for active repression in ARP-1/ COUP-TFII comprises residues 210 to 414, while the domain involved in transrepression extends only to residue 399, corresponding to methionine 406 in COUP-TFI. A possible explanation for these differences might be the fact that entirely different assay systems were employed in the two studies to characterize functional domains of the two highly homologous proteins. Considering the finding that removal of residues 400 to 414 of ARP-1/COUP-TFII abolished active repression without affecting transrepression, it is tempting to speculate that transrepression represents the predominant mechanism underlying repressor activity of the protein.
The AF-2 AD core domain of ARP-1/COUP-TFII is essential for repressor activity, while the hinge region is dispensable for repression. Transcriptional repression by the unliganded TR␤ has been studied extensively (2) (3) (4) 16) . The segment comprising residues 175 to 442 of the TR␤ LBD has been defined as the active silencing domain (3, 4) (Fig. 12B) . The region of the to ϩ121) , was determined in transient-transfection assays as described in the legend to Fig. 1. (C) In the upper part, the effect of overexpression of ARP-1/COUP-TFII on transcriptional activity of a CAT construct containing the minimal apo-B promoter fragment (positions Ϫ30 to ϩ121) which was induced by cotransfection with an expression plasmid for TBP is shown. The middle part displays the effect of overexpression of a fusion protein between the GAL4 DBD and the carboxy-terminal repression domain of ARP-1/COUP-TFII on TBP-induced transcriptional activity of a CAT construct in which three copies of a GAL4 recognition site (17-mer) were inserted upstream of the minimal apo-B promoter fragment (positions Ϫ30 to ϩ121). In the lower part, the effect of overexpression of the ARP 399 mutant on transcriptional activity of the 17-mer TATA-CAT construct induced by a GAL4-DBD-HNF-4(147-455) fusion protein is displayed. Diagrams of the artificial promoter CAT constructs are shown on the left in all panels, and CAT activities of the promoter constructs in the presence of wild-type or Flu-modified ARP-1/COUP-TFII proteins are summarized on the right. CAT activities (Ϯ standard deviations) are expressed relative to that of the CAT construct cotransfected with empty control plasmids, which was set at 100%. Numbers in parentheses represent the number of independent transfections performed for each construct. TR␤ LBD interacting with N-CoR has been localized to residues 206 to 235 (CoR box) (21) . Comparison of the silencing domain of TR␤ with the minimal repression domain of ARP-1/COUP-TFII, as defined in the present study, reveals two important differences. First, the hinge region containing the CoR box is essential for silencing activity of the unliganded TR␤, but this domain is dispensable for repressor activity of ARP-1/COUP-TFII. This finding is in line with the fact that the conserved motif Ala223-His224-Thr227 (66) , located at the carboxy-terminal end of H1 in TR␤, which is essential for binding of the corepressor, is absent in H1 of ARP-1/COUP-TFII. This observation, however, does not preclude interaction of a corepressor protein with a different domain within the carboxy terminus of ARP-1/COUP-TFII, as has been demonstrated for Rev-erbA␣ or RVR (13) . Second, deletion of the AF-2 AD core of TR␤ results in a strong constitutive silencer, which is unable to release a corepressor protein and to activate transcription upon binding of a ligand (3, 4, 66) , while the presence of the AF-2 AD core is critical for repressor activity of ARP-1/COUP-TFII. The finding that a domain which is involved in transactivation by other receptors is required for repressor activity of ARP-1/COUP-TFII is puzzling. It may indicate that repression by ARP-1/COUP-TFII involves interaction of its repressor domain with a coactivator protein, perhaps in a nonproductive way, thereby interfering with transcriptional activation mediated by other transactivators employing the same coactivator protein. The finding that trans repression by ARP-1/COUP-TFII affects several different groups of transactivators is consistent with such a hypothesis. Another possible explanation would be that the AF-2 AD core of ARP-1/COUP-TFII participates in the interaction with a putative corepressor protein.
Integrity of the ninth heptad repeat is essential for repressor activity. From the crystal structure of RXR␣, it is evident that its homodimerization interface is formed mainly by H10, containing the ninth heptad repeat, and, to a lesser extent, by H9 and the loop between H7 and H8 (7). H10, the dimerization helix, is attached to the LBD core through a set of five hydrophobic contacts (7) and may thus, in addition to its role in dimerization, also serve an important role in stabilizing the overall structure of the LBD. As shown in Fig. 4 , substitutions of single amino acids within the ninth heptad repeat of ARP-1/COUP-TFII did not affect repressor activity in our experimental system, while simultaneous introduction of three mu-tations at conserved residues within this domain (Leu363Arg, Leu364Ser, and Leu367Phe) strongly reduced repressor activity and resulted in a concomitant loss of DNA binding. This observation can be interpreted in several ways. It may indicate that homodimerization or heterodimerization of ARP-1/ COUP-TFII is a prerequisite for its repressor activity, or it may suggest that a conformational change resulting from the alteration of the ninth heptad leads to loss of repressor function. Alternatively, the ninth heptad repeat may play a role in the interaction of ARP-1/COUP-TFII with a protein, other than a nuclear receptor, that is important for repressor activity. The latter possibility, however, appears to be unlikely, since the ninth heptad repeat, being involved in homodimerization, is most likely not available for interaction with other proteins. At present it cannot be decided which of these possibilities is most consistent with the role of the ninth heptad repeat in repressor activity of ARP-1/COUP-TFII.
Mechanism of transcriptional repression by ARP-1/COUP-TFII. Our results with several mutants which are unable to bind to DNA but nevertheless efficiently repress transcriptional activity of the apo-B promoter and the finding that the presence of its cognate DNA binding site is not required for repression by ARP-1/COUP-TFII (Fig. 3, 6, 8 , and 10) provide strong evidence for the existence of a DNA-binding-independent mechanism for repression involving protein-protein interaction between ARP-1/COUP-TFII and other proteins important in transcriptional control, such as transactivators or coactivators.
Recently, COUP-TFI has been shown to repress transcriptional activity by a DNA-binding-independent mechanism termed transrepression. Heterodimerization between COUP-TFI and RXR, TR, or RAR has been proposed as the molecular mechanism underlying transrepression. Our study reveals that transcriptional activity induced by HNF-4 is likewise repressed by ARP-1/COUP-TFII in the absence of its cognate DNA binding site (Fig. 10) . HNF-4 has been found to form exclusively homodimers (23) . Thus, it appears unlikely that heterodimerization between HNF-4 and ARP-1/COUP-TFII is involved in the transrepression observed in these experiments.
Possible candidates for coactivators interacting with COUPTFs include proteins of the p300/CBP family, which play a crucial role in transrepression of AP-1 by the glucocorticoid receptor (24) . The observation that in our experimental system overexpression neither of p300 nor of CBP was able to relieve repression by ARP-1/COUP-TFII (Fig. 11) argues against this hypothesis. It has also been suggested that competition for heterodimer formation with RXR might be involved in the mechanism of repression by COUP-TFs. Overexpression of RXR␣ did not result in relief of transcriptional repression by ARP-1/COUP-TFII in our experiments (Fig. 11) . This result strongly argues against a major contribution of such a mechanism in repression of apo-B gene promoter activity by ARP-1/COUP-TFII.
Transcriptional activity mediated by transactivators binding to recognition sites for HNF-4, HNF-3, or C/EBP was repressed by ARP-1/COUP-TFII, while basal transcription or transcriptional activity induced by Sp1 or ATF was unaffected. Our finding that ARP-1/COUP-TFII is unable to affect basal transcription is in disagreement with earlier reports by Cooney and coworkers (10) . Those authors found that COUP-TFI represses basal activity of a thymidine kinase CAT construct in CV1 cells. The discrepancy between their results and ours may reflect differences in reporter constructs and cell lines. Our results are most consistent with the idea that interaction between ARP-1/COUP-TFII and a coactivator protein serving a role as a common mediator of transcriptional activation induced by HNF-4, C/EBP, and HNF-3, but not by Sp1 or ATF, is involved in repression.
Despite the fact that DNA binding is dispensable for repressor activity of ARP-1/COUP-TFII, the presence of the evolutionary highly conserved DBD of the protein was found to be essential for repression in our experiments. This result provides strong evidence that the DBD of ARP-1/COUP-TFII not only is required for interaction with DNA but also is involved in its transrepressor activity. This finding is consistent with previous results (24, 67) demonstrating that the DBD of RAR is involved in transrepression of AP-1-induced transcriptional activity, a mechanism which does not require DNA binding of RAR. Based upon our results, however, we cannot decide whether the DBD of ARP-1/COUP-TFII harbors an inherent repressor activity or whether its major function is to stabilize a proper conformation of the carboxy-terminal repression domain of the protein.
In conclusion, our results demonstrate that ARP-1/COUP-TFII possesses a transferable active repression domain comprising residues 210 to 414, which does not coincide with the regions of the protein required for transrepression, including the DBD and the segment comprising residues 193 to 399. Comparison of the repression domain of the protein with the recently published crystal structures of LBDs of other members of the nuclear receptor superfamily (7, 53, 59, 66) reveals that it includes H3 to H12. These helices constitute the hydrophobic core of the protein, the main part of the ligand binding pocket, the dimerization interface, and the AF-2 AD core. The ARP-1/COUP-TFII repression domain, however, does not contain the hinge region, which was found to be essential for interaction with corepressor proteins in the cases of TR and RAR. For transrepression, which appears to be the predominant mechanism underlying repression by ARP-1/COUP-TFII, the presence of the DBD in conjunction with the segment comprising residues 193 to 399 is required. Identification of proteins interacting with these domains of ARP-1/COUP-TFII and elucidation of their crystal structures will ultimately be required to gain a more complete understanding of the molecular mechanism underlying transcriptional repression by this protein.
